HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Lupin Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Lupin Intelligence Report

Generated from 20 signals · 3 evidence sources

Type

Company Intelligence Report

Generated

Aug 5, 2026

Confidence

Moderate Confidence · 71%

Evidence

111 items

Sources

17

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Lupin maintains an active intelligence profile across Women's Health, Contraceptive, Metabolic Disorders, Urea Cycle Disorders, Anesthesia. 20 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 71% across 3 tracked sources. Highest-priority development: FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer. Regulatory precedent. Why this matters: illustrates how regulators handled a comparable approval decision relevant to Lupin; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA Approves First Generics of Gilotrif (afatinib) Tablets

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA AP — OXYCODONE AND ACETAMINOPHEN (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    FDA AP — ADRENALIN (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    Notice: Register of authorised online sellers of medicines in Northern Ireland

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA AP — MYCOPHENOLATE MOFETIL HYDROCHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    Cancer Clinical Trial Eligibility Criteria: Performance Status

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 2161 with buyer quality 4 (Low Priority). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA Approves First Generics of Gilotrif (afatinib) Tablets

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — OXYCODONE AND ACETAMINOPHEN (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ADRENALIN (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Notice: Register of authorised online sellers of medicines in Northern Ireland

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • FDA AP — MYCOPHENOLATE MOFETIL HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Cancer Clinical Trial Eligibility Criteria: Performance Status

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SUGAMMADEX SODIUM (ORIG)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SUGAMMADEX SODIUM (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SUGAMMADEX SODIUM (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BREXAFEMME (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Lupin's Lenalidomide ANDA214398 Receives Abbreviated Approval

    Oncology · Immunomodulator

  • FDA Approves Glycerol Phenylbutyrate Application by Lupin

    Metabolic Disorders · Urea Cycle Disorders

  • Lupin's Glycerol Phenylbutyrate Receives FDA Approval Status

    Metabolic Disorders · Urea Cycle Disorder

  • Lupin's ANDA201446 for Levonorgestrel Receives FDA AP Status

    Women's Health · Contraceptive

  • Lupin's Sugammadex Sodium ANDA214338 Receives Approval Status

    Anesthesia · Neuromuscular Blockade

  • Lupin's Fosaprepitant Dimeglumine Supplement Receives FDA AP Status

    Oncology · Antiemetic

  • Lupin's Diazepam ANDA220365 Receives Approval Status from FDA

    Neurology · Anxiolytic

  • Lupin's Lenalidomide ANDA214398 Receives FDA Approval Status

    Oncology · Small Molecule

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.